Here are some sample widgets you could interact with from this dashboard:
Keytruda Sales Sky Rocketed North of $11 Billion In 2019Keytruda sales have grown at a CAGR of 284% from $55 million in 2014 to $11 billion in 2019, led by a series of approvals for multiple indications. Our dashboard Keytruda Valuation highlights how big can Keytruda be in each indication, and estimates overall value for the drug
In sections below we highlight approvals bagged by Keytruda each year
Keytruda Sales against summary of approved indications
2015: +2nd line lung
2016: +1st line lung
2017: +Gastric, Bladder, Hodgkins
2018: +Cervical, Liver, Expanded lung
2019: +Renal, Expanded in Head and Neck
2014: Keytruda Sales $55 Million After Bagging Approval For Skin Cancer
The U.S. FDA on Sep 4, 2014 granted approval to Keytruda for treatment of patients with advanced or unresectable melanoma, who are no longer responding to other drugs.Keytruda became 6th melanoma treatment approved since 2011, after Yervoy (BMS), Pegasys (Roche), Zelboraf (Roche), Tafinlar (GSK), and Mekinist (GSK).
2015: Sales Grew 10x To $586 Million After Second Line Lung Cancer Approval
Keytruda was approved by the U.S. FDA to treat patients with advanced non-small cell lung cancer (NSCLC), whose disease has progressed after other treatments, in Oct 2015. In 2015, Bristol-Myers Squibb's Opdivo was also approved for lung cancer treatment. Later in December 2015, Keytruda was approved to include the first-line treatment of patients with metastatic melanoma.
2016: Keytruda Sales Grew 1.4x To $1.4 Billion After Approval For Lung Cancer First Line Treatment
Keytruda in Oct 2016 was approved for the first-line treatment of patients with metastatic non-small cell lung cancer, whose tumors have high PD-L1 (a type of protein) expression, with no epidermal growth factor receptor (EGFR) mutations and anaplastic large-cell lymphoma kinase (ALK) genomic tumor aberrations.Keytruda became the first and only first line treatment option for such patients. Earlier in Aug 2016, Keytruda also bagged the approval for the treatment of patients with head and neck squamous cell carcinoma (HNSCC), with disease progression on or after platinum-containing chemotherapy.
2017: Sales Grew 1.7x To $3.8 Billion After Approval For Gastric & Bladder Cancer And Hodgkin Lymphoma
In Mar 2017, Keytruda was approved for the treatment of patients with refractory classical Hodgkin lymphoma (cHL), or who have relapsed after three or more prior lines of therapy.In May 2017, FDA expanded the use of Keytruda in lung cancer as a first line treatment, irrespective of PD-L1 levels. During the same month, the U.S. FDA approved Keytruda for the first line treatment of patients with bladder cancer, who are ineligible for cisplatin-containing chemotherapy.Later in Sep 2017, Keytruda was approved for the treatment of patients with gastric cancer, with disease progression on or after two or more prior lines of therapy.
2018: Keytruda Sales Grew 88% To $7.2 Billion After Approval For Cervical & Liver Cancer, And Expanded Use In Lung Cancer
In Jun 2018, the U.S. FDA approved Keytruda for the treatment of patients with cervical cancer with disease progression on or after chemotherapy. During the same month, Keytruda was also approved for the treatment of patients with refractory primary mediastinal large B-cell lymphoma (PMBCL), which is a type of Hodgkin Lymphoma, who have relapsed after two or more prior lines of therapy. In Aug 2018, Keytruda bagged approval for extended use in lung cancer, with no EGFR or ALK genomic tumor aberrations.Later in Nov 2018, Keytruda was approved for the treatment of patients with hepatocellular carcinoma (HCC), a cancer arising from liver cells, who have been previously treated with sorafenib.
2019: Sales Grew 55% To $11 Billion As Keytruda Bags Approval For Renal Cancer, And Expanded Use In Lung And Head & Neck
Keytruda bagged approval for the adjuvant treatment of patients with melanoma with involvement of lymph nodes following complete resection in Feb 2019.The U.S. FDA in Apr 2019 approved Keytruda as monotherapy for the first-line treatment of patients with stage III non-small cell lung cancer who are not candidates for surgical resection or definitive chemoradiation, with no EGFR or ALK genomic tumor aberrations.In Apr 2019, Keytruda was approved in combination with Pfizer's Inlyta, for the first-line treatment of patients with advanced renal cell carcinoma (RCC).In Jun 2019, Keytruda was approved as monotherapy for the first-line treatment of patients with recurrent head and neck squamous cell carcinoma (HNSCC).
See our complete set of analyses for Merck.